Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision-making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. Beam is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
CertiK is a pioneer in blockchain security, leveraging best-in-class AI technology to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, CertiK’s mission is to secure the web3 world. CertiK applies cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness.
The DFINITY Foundation’s mission is to build, promote, and maintain the Internet Computer — the world’s first web-speed, internet-scale public blockchain. It enables smart contracts to securely serve interactive web content directly into the browsers of end users, making it possible to build dapps, DeFi, open internet services, and enterprise systems that are capable of operating at hyperscale. The Internet Computer uses smart contracts to power an emerging decentralized ecosystem of interoperable dapps and services, where nearly every system and service can run in reimagined form on public blockchain.
Cobo is a globally trusted leader in digital asset custody solutions. Established in 2017 and headquartered in Singapore, our industry-leading custody technologies inspire confidence in digital asset ownership by enabling safe and efficient management of digital assets and interactions with Web 3.0. As a pioneering omni-custody platform, Cobo offers the full spectrum of custody technologies designed specifically to cater to the unique needs of institutions. From full custody based on bank-grade hardware security modules (HSMs), to co-managed custody built on advanced multi-party computation (MPC) technology, and fully decentralized self-custody based on smart contracts, we empower institutions to secure and manage their digital assets their way. In addition, Cobo provides Wallet-as-a-Service, SuperLoop (off-exchange settlement network), and Argus (on-chain DeFi strategies and tools with role-based access controls). Trusted by over 500 institutional clients with billions of dollars in assets under custody, our client base spans across exchanges, mining pools, investment funds, web3 developers, crypto-native firms, to traditional institutions from Asia, Europe, the Middle East, and North and South America. At Cobo, we are committed to security and regulatory compliance. The Company is SOC 2 Type 1 and Type 2 compliance-certified and licensed in the US, Singapore, Hong Kong, Lithuania and Dubai (provisional approval for Virtual Asset License). Cobo is backed by top-tier global investors including DST Global, A&T Capital, IMO Ventures, and DHVC Capital. In September 2021, Cobo completed its USD 40 million Series B financing round.
PathAI’s services solve challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making accurate diagnoses for every patient, every time. The company was founded in 2016 and is based in Boston, Massachusetts.
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer.
Founded in 2018 with offices across three countries and two continents, InfStones is the world's leading blockchain infrastructure provider. Currently, InfStones provides services to large institutional clients around the globe, supporting thousands of nodes on more than 50 public blockchains through its universal platform.
Viz helps physicians to identify anomalies in brain scans through machine learning. The company leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat them. It uses deep learning algorithms to identify a suspected large vessel occlusion, a particularly disabling type of stroke, in a CT scan and alerts the stroke team specialist within minutes. Viz has developed deep learning algorithms to analyze brain scans for large vessel occlusions (LVOs), a disabling type of stroke. The company also allows the stroke center’s clinicians to rapidly share images back and forth. Viz's mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce the time to treatment and improve access to care. Viz was founded in 2016 and is based in San Francisco, California.
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.